TABLE 2.

Clinical Trials in NEPC focused on TFs, chromatin modifiers and other proteins.

Clinical trial number	Drug	Efficacy
NCT05413421 (Phase I/Ib)	PRC2 inhibitor, ORIC-944	Not reported (ongoing)
NCT01799278 (Phase II)	AURKA inhibitor, Alisertib	A subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit (Beltran et al., 2019)
NCT04702737 (Phase 1b)	DLL3 bispecific T Cell engager, AMG 757	Not reported (ongoing)
NCT05268666 (Phase I/II)	LSD1/HDAC6 inhibitor, JBI-802	Not reported (ongoing)
NCT02711956 (Phase Ib/IIa)	BETi, ZEN-3694	ZEN-3694 plus enzalutamide demonstrated acceptable tolerability and potential efficacy in patients with ASI-resistant mCRPC (Aggarwal et al., 2020)